Close Menu
    What's Hot

    Editor’s Letter – Volume 4, Issue 5, May 2025

    14 May 2025

    New Data Shows the Extent to Which American Seniors Are Missing Out by Lapsing or Surrendering their Life Insurance Policy

    14 May 2025

    Buy-Ins To Buy-Outs Appear Stalled As Deal Complexity, Administration Resources Pose Obstacles

    14 May 2025
    Facebook X (Twitter) Instagram
    Instagram LinkedIn X (Twitter)
    Life Risk News
    • Home
    • Features

      New Data Shows the Extent to Which American Seniors Are Missing Out by Lapsing or Surrendering their Life Insurance Policy

      14 May 2025

      Buy-Ins To Buy-Outs Appear Stalled As Deal Complexity, Administration Resources Pose Obstacles

      14 May 2025

      Is Servicing an Overlooked Source of Life Settlement Alpha?

      14 May 2025

      Q&A: Shelly Beard, Managing Director, WTW

      14 May 2025

      Longevity Tech to Emerge as Distinct Sub-Sector of Venture Capital Market?

      14 May 2025
    • Commentary

      UK Life Insurers to Benefit from Robust Bulk Annuity Market in 2025

      14 May 2025

      The Power of Uncorrelated Diversification During Market Volatility

      14 May 2025

      Overseeing BPA Growth Safely

      14 May 2025

      Could Climate Change Cause the Buy-In Market To Collapse?

      10 April 2025

      ICS vs Solvency II: Comparing Risk Corrections for Illiquid Liabilities

      10 April 2025
    • Events
    • Magazine
    • News

      Life Insurance Settlement Association Publishes Latest Market Data Collection Survey Results

      13 May 2025

      UK Aggregate Defined Benefit Pension Fund Surplus Down Again in April

      12 May 2025

      Monument Re Transfers Greycastle Portfolio to RGA

      12 May 2025

      Cancer Research UK Pension Scheme Completes Bulk Purchase Annuity Buy-In With Standard Life

      12 May 2025

      AQA Education Completes Bulk Purchase Annuity Buy-In With Rothesay

      12 May 2025
    Subscribe
    Life Risk News
    Home » Actual-to-Expected Apocrypha

    Actual-to-Expected Apocrypha

    Features 15 December 2023Vince GranieriBy Vince Granieri
    Twitter LinkedIn Email
    Share
    Twitter LinkedIn Email

    A few months ago, Life Risk News published my commentary article regarding life expectancy (LE) apocrypha. Given the positive feedback I received, I decided to write a follow-up, focusing on industry suppositions about actual to expected analysis (A-to-E), no stranger to controversy over the years.  

    Although many philosophies and theories about LEs have been proffered by life expectancy providers, virtually every type of participant in the life settlement market has contributed to the apocrypha surrounding actual to expected analysis.  

    Let’s first define actual to expected analysis. According to the actuarial profession, it is the process of calculating and analyzing A/E ratios over a selected time period, (i.e., actual deaths in a group of lives being evaluated, over a specified period divided by the expected deaths, the number of deaths statistically expected over the same period). 

    With that in mind, consider the following assertions that have been expressed by industry participants, but in my view, are not valid: 

    A-to-E is a perfect measure of LE provider accuracy 

    It isn’t, at least, if presented as a single number with few or no insights into the methodology behind it. In fact, a single number A-to-E tells us very little (just as using a single number LE instead of the underlying curve can be misleading). An extreme example would be a block of policies where the A-to-E on half of the policies is 150, and the other half is 50; this makes the overall A-to-E 100. Is that perfection? No, it is nowhere near perfect; in fact, it’s not even mediocre.  

    Further, the nature of the A-to-E calculation introduces bias over time. A-to-E trends to 100, even if insureds do not die when expected. For example, an insured who was given a very short LE, say 12 months, lives 75 months and then dies. In month 76, the A-to-E on this policy is 100. That’s not helpful. 

    A-to-E is worthless in assessing LE provider accuracy 

    Based on the above-noted weaknesses, A-to-E seems worthless. Not true! The key to unlocking the value of A-to-E is in breaking it down: by age, by gender, by smoking status, by impairment, by mortality multiplier, by year of underwriting, etc. If we turn that single number into many numbers, true insights can be obtained. 

    An A-to-E of 100 is a perfect score 

    We as an industry did ourselves no favors by proclaiming 100 to be the ideal for A-to-E. The ideal is a consistent A-to-E, when broken down by age, gender, smoking status, etc. Consistency from those specific measurements can be relied upon, and adjustments made to improve accuracy. For example, if an LE provider’s A-to-E is 80% across gender, face amount, year underwritten, impairment, multiplier, etc., it is easy to adjust their LEs to eliminate their bias by multiplying each mortality rate by 80%. On the other hand, if there are large differences when these calculations are broken out, it’s almost impossible to rely on the LEs or correct for inconsistent bias. 

    In two recent industry meetings on both sides of the Atlantic, similar questions were asked: If all you LE providers have A-to-Es around 100, why are your individual LEs so different? At the very minimum, it is a result of the fact that the A-to-E statistic, which is an average, bears little resemblance to the individual policies that make it up. There may be different methods and assumptions employed as well. 

    Although exploring different A-to-E methodologies is beyond the scope of this commentary, allow me to touch on a particularly important assumption – incurred but not reported deaths ( IBNR, for short).  

    IBNR is a perfect example of good logic gone bad in our business. It’s reasonable to expect that when someone dies, that information is not reported for some time. Actuaries have recognized this for decades and that is the genesis of the IBNR assumption. Depending on the time lapse between the period we are studying and the calculation date, most actuaries agree that a 3-5% IBNR is reasonable. 

    Given the importance of the statistic, A-to-E studies should include results with and without IBNR so users of the study can adjust the assumptions should they desire. Unfortunately, many studies do not disclose IBNR, even when it drives the results. I have heard of IBNR assumptions as high as 60%, although the worst I have actually seen was 38%. All in the name of getting a 100 A-to-E. 

    How do we make this A-to-E statistic meaningful? By standardizing its calculation, disclosing the underlying methodology and presenting meaningful breakdowns.  

    A-to-E can be calculated from LEs that do not include a mortality table 

    Not true. Think about it; if there is no mortality table, how does one calculate expected deaths for a given period? For example, let’s assume an LE of 72 months and we want to calculate the A-to-E after 12 months has elapsed. We can easily count the actual deaths. But not the expected deaths. 

    Some LE providers have used this to their advantage. They never provided a mortality or survival curve with their LEs but insisted that all A-to-E calculations utilize the actual LEs sent to customers. Notice the wording – not the actual survival curves sent to customers, the actual LEs. When it came time to calculate A-to-E, they simply chose a mortality table with low early duration deaths to back solve their LEs into and they could artificially create an A-to-E close to 100.  

    A lesson learned is customers should require their LE provider to give them the expected survival curves underlying their LEs. Also, they should question any A-to-E results that are not based on the actual survival curves in place at the time the LEs were issued (although there might be a good reason to present a modified analysis along with the historical analysis as seen below). 

    There are no rules regarding A-to-E calculations 

    The American Academy of Actuaries set forth rules for calculating A-to-E in what they call Actuarial Standard of Practice (ASOP) Number 48, published in December 2013, to be applied to work done after April 2014. Recognizing that certain misleading practices in calculating A-to-E had crept into the public forum, ASOP 48 was promulgated by the governing actuarial body. Although its official title was Life Settlement Mortality, it contained guidelines for A-to-E calculations too.  

    ASOP 48 noted two specific bases for use in A-to-E calculations: historical basis and modified basis. Historical basis was the use of a survival curve developed from the base mortality table, mortality improvement factors, mortality multipliers, and other pertinent information for each LE that was used on the original underwriting date. Modified basis was the substitution of any pertinent information other than what was used on the date of original underwriting (for example, a different mortality table or mortality multiplier). Many LE providers calculate A-to-E using their current mortality tables and methods. 

    Importantly, ASOP 48 clearly states that if a modified basis is presented that the historical basis also be presented if the actuary believes doing so is appropriate. To be fair, this allows some wiggle room, which is unfortunate. However, the actuary is required to disclose why those results are not provided, if the historical basis is not presented alongside the modified basis. I cannot think of a good reason why the historical basis results should not be disclosed. I can think of many bad reasons. 

    The Historical Basis A-to-E is preferable to a modified basis that utilizes current methodology 

    Some folks suggest that the only meaningful A-to-E statistic is the historical basis, i.e., the mortality table and mortality multiplier that was used to create the LE initially. Certainly, this is important information, and it speaks to the accuracy of an LE provider’s work over a long period of time. 

    However, a modified basis A-to-E, under the right circumstances, is also very useful. Use of the LE provider’s current mortality table and underwriting debits is particularly valuable in that it indicates whether the modifications the LE provider made to their tables and debiting over time resulted in a more accurate product going forward. 

    Substituting a VBT will not affect LE accuracy 

    Advocates of the VBT should not be surprised to find that it overstates deaths vis-à-vis a life settlements mortality table. Therefore, substituting the VBT in a life settlement underwriting will result in an understated LE. The corresponding A-to-E using this approach can be significantly lower – 20 points in our recent calculations.  

    A-to-E cannot be helpful in determining underwriting changes 

    Like many other assertions in this paper, under certain circumstances, it could be true, even though under others, it is clearly false. It is true that the single number A-to-E is virtually useless in determining changes. However, as we saw above, more granular breakdowns can provide actionable information. For example, a by impairment or age band breakdown can point to areas of concern.  

    This brings us to the final topic. Your due diligence should include a discussion with the LE provider on how, how often, and under what circumstances are changes implemented in their LE methodology. Data should be the decider of the timing. Regression models can be utilized to determine changes in the debits and credits, but A-to-E (of the portion of lives in our database that have no or very minor impairments) could be used to determine if base mortality table changes are warranted. 

    A-to-E is imperfect and imperfect analyses of A-to-E will lead to erroneous conclusions. When used properly, A-to-E can be a useful tool in assessing LE provider performance and prescribing modifications to consider when using LE providers’ products.  

    Vince Granieri is CEO at Predictive Resources


    Any views expressed in this article are those of the author(s) and do not necessarily reflect the views of Life Risk News or its publisher, the European Life Settlement Association

    2023 - December Longevity and Mortality Trends Longevity Risk Volume 2 Issue 12 - December 2023
    Share. Twitter LinkedIn Email

    Related Posts

    UK Life Insurers to Benefit from Robust Bulk Annuity Market in 2025

    14 May 2025

    The Power of Uncorrelated Diversification During Market Volatility

    14 May 2025

    Overseeing BPA Growth Safely

    14 May 2025

    Could Climate Change Cause the Buy-In Market To Collapse?

    10 April 2025

    Comments are closed.

    Most Popular

    New Data Shows the Extent to Which American Seniors Are Missing Out by Lapsing or Surrendering their Life Insurance Policy

    14 May 2025

    Buy-Ins To Buy-Outs Appear Stalled As Deal Complexity, Administration Resources Pose Obstacles

    14 May 2025

    Is Servicing an Overlooked Source of Life Settlement Alpha?

    14 May 2025

    UK Life Insurers to Benefit from Robust Bulk Annuity Market in 2025

    14 May 2025
    Ad

    Your trusted source for capital markets participation in Life Risk

    X (Twitter) Instagram LinkedIn
    Life Risk
    • About Life Risk News
    • Get In Touch
    • Our Team
    • Copyright Notice
    • Terms and Conditions
    • Privacy Policy
    • Sitemap
    Coverage
    • Home
    • Features
    • Events
    • Commentary
    Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
    Cookie SettingsAccept All
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT